<DOC>
	<DOC>NCT01750190</DOC>
	<brief_summary>The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in chronic kidney disease patients who are not on dialysis.</brief_summary>
	<brief_title>A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis</brief_title>
	<detailed_description>There is a screening period of up to 6 weeks, a variable treatment period for individual subjects with a minimum treatment duration of 52 weeks and a maximum treatment duration of time to enroll all subjects plus 52 weeks after the last subject is randomized, and a post-treatment follow-up period of 4 weeks. A total of 600 patients will be randomized in a 2:1 ratio to receive either roxadustat (FG-4592-approximately 400 subjects) or placebo (approximately 200 subjects) in a double-blind manner.</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Chronic kidney disease, Stage 3, 4, or 5, not receiving dialysis Anemia qualified by measurements of hemoglobin values during screening Additional blood work must be in a safe range for study entry Body weight 45 to 160 kg Willingness to use contraception if of childbearing potential Treatment with an erythropoiesisstimulating agent (ESA) within 12 weeks prior to study participation More than one dose of intravenous iron within 12 weeks prior to study participation Blood transfusion within 8 weeks prior to study participation Active infection Chronic liver disease Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot Uncontrolled blood pressure within 2 weeks prior to study participation Renal cell carcinoma History of malignancy, including multiple myeloma or other myelodysplastic syndrome Chronic inflammatory disease that could impact red blood cell production Any prior organ transplant, or a scheduled organ transplantation Anticipated elective surgery that is expected to lead to significant blood loss, or anticipated elective heart procedure Gastrointestinal bleeding Any prior treatment with FG4592 or a HIFPHI Recent use of an investigational drug or treatment, or participation in an investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease (CKD)</keyword>
	<keyword>non-dialysis</keyword>
	<keyword>Hemoglobin (Hb)</keyword>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>erythropoeitin</keyword>
	<keyword>ASP1517</keyword>
	<keyword>erythropoeisis stimulating-agent</keyword>
	<keyword>AZD9941</keyword>
</DOC>